Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash from Operations: 2019-2025

Historic Cash from Operations for Benitec Biopharma (BNTC) over the last 5 years, with Jun 2025 value amounting to -$8.2 million.

  • Benitec Biopharma's Cash from Operations fell 149.77% to -$8.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$23.6 million, marking a year-over-year decrease of 21.63%. This contributed to the annual value of -$23.6 million for FY2025, which is 21.63% down from last year.
  • Benitec Biopharma's Cash from Operations amounted to -$8.2 million in Q2 2025, which was down 166.53% from -$3.1 million recorded in Q1 2025.
  • Benitec Biopharma's 5-year Cash from Operations high stood at -$2.0 million for Q1 2021, and its period low was -$8.2 million during Q2 2025.
  • In the last 3 years, Benitec Biopharma's Cash from Operations had a median value of -$4.6 million in 2024 and averaged -$5.1 million.
  • In the last 5 years, Benitec Biopharma's Cash from Operations tumbled by 160.08% in 2021 and then skyrocketed by 49.97% in 2025.
  • Quarterly analysis of 5 years shows Benitec Biopharma's Cash from Operations stood at -$3.3 million in 2021, then tumbled by 76.25% to -$5.9 million in 2022, then climbed by 8.76% to -$5.3 million in 2023, then crashed by 43.93% to -$7.7 million in 2024, then tumbled by 149.77% to -$8.2 million in 2025.
  • Its Cash from Operations was -$8.2 million in Q2 2025, compared to -$3.1 million in Q1 2025 and -$7.7 million in Q4 2024.